Fed. Circ. Says PTAB Wrongly Nixed Patent In Eli Lilly Case

By Ryan Davis (February 28, 2017, 7:34 PM EST) -- The Federal Circuit ruled Tuesday that the Patent Trial and Appeal Board incorrectly invalidated an Eli Lilly-challenged patent on treating a condition related to erectile dysfunction, saying that the board did not sufficiently establish the invention was obvious.

In a 2-1 decision, a three-judge panel vacated the board's inter partes review decision that a patent the Los Angeles Biomedical Research Institute accused Eli Lilly and Co.'s drug Cialis of infringing would be obvious in light of three prior art references. That finding was based on an incorrect claim construction, and the board did not make sufficient obviousness findings, the panel majority...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!